Cgrp receptor antagonists: Toward a novel migraine therapy

Current Pharmaceutical Biotechnology

Volumn 12, Issue 10, 2011, Pages 1671-1680

  Salvatore, C A ^a   Kane, S A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

CGRP; CGRP receptor antagonist; Migraine; Neuropeptide; Trigeminovascular

Indexed keywords

BMS 694153; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; MK 3207; OLCEGEPANT; PLACEBO; RIZATRIPTAN; SB 273779; TELCAGEPANT; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ANALGESIA; CLINICAL FEATURE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HUMAN; MIGRAINE; NAUSEA; NONHUMAN; PHONOPHOBIA; PHOTOPHOBIA; RECEPTOR AFFINITY; REVIEW; SENSORY NERVE CELL;

EID: 80053530076     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111798357401     Document Type: Review

References (103)

1. Stovner, L.J.; Hagen, K.; Jensen, R.; Katsarava, Z.; Lipton, R.B.; ScHer, A.I.,; Steiner, T.J.; Zwart, J.A. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia, 2007, 27(3), 193-210.
2. Berg, J.; Ramadan, N.M. Societal Burden of Headache. In: The Headaches, 3rd ed.; Olesen, J., Goadsby, P.J., Ramadan, N.M., Tfelt-Hansen, P., Welch, K.M.A., Eds.; Lippincott Williams & Wilkins, Philadelphia, 2006; pp. 35-42.
3. Lipton, R.B.; Diamond, S.; Reed, M.; Diamond, M.L.; Stewart, W.F. Migraine diagnosis and treatment: results from the American migraine study II. Headache, 2001, 41(7), 638-645.
4. Hargreaves, R. New migraine and pain research. Headache, 2007, 47(Suppl. 1), 26-43.
5. Dodick, D.W. Triptan nonresponder studies: implications for clinical practice. Headache, 2005, 45(2), 156-162.
6. Dodick, D.; Lipton, R.B.; Martin, V.; Papademetriou, V.; Rosamond, W.; MaassenVanDenBrink, A.; Loutfi, H.; Welch, M.; Goadsby, P.J.; Hahn, S.; Hutchinson, S.; Matchar, D.; Silberstein, S.; Smith, T.R.; Purdy, A.; Saiers, J. Consensus statement: cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache, 2004, 44(5), 414-425.
7. Edvinsson, L.; Uddman, E.; Wackenfors, A.; Davenport, A.; Longmore, J.; Malmsjo, M. Triptan-induced contractile (5-HT1B receptor) responses in human cerebral and coronary arteries: relationship to clinical effect. Clin. Sci. (Lond.), 2005, 109(3), 335-342.
8. Edvinsson, L. Functional role of perivascular peptides in the control of cerebral circulation. Trends in NeuroSci., 1985, 8, 126-131.
9. Ray, B.S.; Wolff, H.G. Experimental studies on headache: pain sensitive structures of the head and their significance in headache. Arch. Surgery, 1940, 41, 813-856.
10. Linde, M. Migraine: a review and future directions for treatment. Acta. Neurol. Scand., 2006, 114(13), 71-83.
11. Rasmussen, B.K. Epidemiology of Migraine. In: The Headaches, 3rd ed., Olesen, J., Goadsby, P.J., Ramadan, N.M., Tfelt-Hansen, P., Welch, K.M.A., Eds.; Lippincott Williams & Wilkins, Philadelphia, 2006; pp. 235-242.
12. Lipton, R.B.; Bigal, M.E.; Diamond, M.; Freitag, F.; Reed, M.L.; Stewart, W.F. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology, 2007, 68(5), 343-349.
13. Kelman, L. The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. Headache, 2004, 44(9), 865-872.
14. Dahlof, C.; Linde, M. One-year prevalence of migraine in Sweden: a population-based study in adults. Cephalalgia, 2001, 21(6), 664-671.
15. Eriksen, M.K.; Thomsen, L.L.; Andersen, I.; Nazim, F.; Olesen, J. Clinical characteristics of 362 patients with familial migraine with aura. Cephalalgia, 2004, 24(7), 564-575.
16. Headache Classification Infcommittee of the International Headache Society. The international classification of headache disorders. Cephalalgia, 2004, 24(Suppl. 1), 8-160.
17. Amara, S.G.; Jonas, V.; Rosenfeld, M.G.; Ong, E.S.; Evans, R.M. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature, 1982, 298(5871), 240-244.
18. Alevizaki, M.; Shiraishi, A.; Rassool, F.V.; Ferrier, G.J.M.; MacIntyre, I.; Legon, S. The calcitonin-like sequence of the β CGRP gene. FEBS Lett., 1986, 206(1), 47-52.
19. Mulderry, P.K.; Ghatel, M.A.; Spokes, R.A.; Jones, P.M.; Pierson, A.M.; Hamid, Q.A.; Kanse, S.; Amara, S.G.; Burrin, J.M.; Legon, S.; Polak, J.M.; Bloom, S.R. Differential expression of β-CGRP and α-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. Neuroscience, 1988, 25(1), 195-205.
20. Brain, S.D.; Grant, A.D. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol. Rev., 2004, 84, 903-934.
21. van Rossum, D.; Hanisch, U.-K.; Quirion, R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci. Biobehav. Rev., 1997, 21(5), 649-678.
22. Brain, S.D.; Williams, T.J.; Tippins, J.R.; Morris, H.R.; MacIntyre, I. Calcitonin gene-related peptide is a potent vasodilator. Nature, 1985, 313(5997), 54-56.
23. Uddman, R.; Edvinsson, L.; Ekman, R.; Kingman, T.; McCulloch, J. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and coexistence of infstance P. Neurosci. Lett., 1985, 62(1), 131-136.
24. Jansen, I.; Uddman, R.; Ekman, R.; Olesen, J.; Ottosson, A.; Edvinsson, L. Distribution and effects of neuropeptide Y, vasoactive intestinal peptide, infstance P, and calcitonin gene-related peptide in human middle meningeal arteries: comparison with cerebral and temporal arteries. Peptides, 1992, 13(3), 527-536.
25. Goadsby, P.J.; Edvinsson, L.; Ekman, R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann. Neurol., 1988, 23(2), 193-196.
26. Zagami, A.S.; Goadsby, P.J.; Edvinsson, L. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides, 1990, 16(2), 69-75.
27. Goadsby, P.J.; Edvinsson, L.; Ekman, R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol., 1990, 28(2), 183-187.
28. Juhasz, G.; Zsombok, T.; Modos, E.A.; Olajos, S.; Jakab, B.; Nemeth, J.; Szolcsanyi, J.; Vitrai, J.; Bagdy, G. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain, 2003, 106(3), 461-470.
29. Tvedskov, J.F.; Lipka, K.; Ashina, M.; Iversen, H.K.; Schifter, S.; Olesen, J. No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann. Neurol., 2005, 58(4), 561-568.
30. Fusayasu, E.; Kowa, H.; Takeshima, T.; Nakaso, K.; Nakashima, K. Increased plasma infstance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods. Pain, 2007, 128(3), 209-214.
31. Cady, R.K.; Vause, C.V.; Ho, T.W.; Bigal, M.E.; Durham, P.L. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache, 2009, 49(9), 1258-1266.
32. Lassen, L.H.; Haderslev, P.A.; Jacobsen, V.B.; Iversen, H.K.; Sperling, B.; Olesen, J. CGRP may play a causative role in migraine. Cephalalgia, 2002, 22(1), 54-61.
33. Petersen, K.A.; Lassen, L.H.; Birk, S.; Lesko, L.; Olesen, J. BIBN4096BS antagonizes human β-calcitonin gene related peptide- induced headache and extracerebral artery dilatation. Clin. Pharmacol. Ther., 2005, 77(3), 202-213.
34. Juhasz, G.; Zsombok, T.; Jakab, B.; Nemeth, J.; Szolcsanyi, J.; Bagdy, G. Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. Cephalalgia, 2005, 25(3), 179-183.
35. Goadsby, P.J.; Edvinsson, L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol., 1993, 33(1), 48-56.
36. Kawai, Y.; Takami, K.; Shiosaka, S.; Emson, P.C.; Hillyard, C.J.; Girgis, S.; MacIntyre, I.; Tohyama, M. Topographic localization of calcitonin gene-related peptide in the rat brain: an immunohistochemical analysis. Neuroscience, 1985, 15(3), 747-763.
37. Inagaki, S.; Kito, S.; Kubota, Y.; Girgis, S.; Hillyard, C.J.; MacIntyre, I. Autoradiographic localization of calcitonin gene-related peptide binding sites in human and rat brains. Brain Res., 1986, 374(2), 287-298.
38. Weiller, C.; May, A.; Limmroth, V.; Juptner, M.; Kaube, H.; Schayck, R.V.; Coenen, H.H.; Diener, H.C. Brain stem activation in spontaneous human migraine attacks. Nat. Med., 1995, 1(7), 658-660.
39. Afridi, S.K.; Giffin, N.J.; Kaube, H.; Friston, K.J.; Ward, N.S.; Frackowiak, R.S.J.; Goadsby, P.J. A positron emission tomographic study in spontaneous migraine. Arch. Neurol., 2005, 62(8), 1270-1275.
40. Steindler, D.A. Trigeminocerebellar, trigeminotectal, and trigeminothalamic projections: a double retrograde axonal tracing study in the mouse. J. Comp. Neurol., 1985, 237(2), 155-175.
41. Patrick, G.W.; Robinson, M.A. Collateral projections from trigeminal sensory nuclei to ventrobasal thalamus and cerebellar cortex in rats. J. Morphol., 1987, 192(3), 229-236.
42. Borsook, D.; Moulton, E.A.; Tully, S.; Schmahmann, J.D.; Becerra, L. Human cerebellar responses to brush and heat stimuli in healthy and neuropathic pain infjects. Cerebellum, 2008, 7(3), 252-272.
43. McLatchie, L.M.; Fraser, N.J.; Main, M.J.; Wise, A.; Brown, J.; Thompson, N.; Solari, R.; Lee, M.G.; Foord, S.M. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature, 1998, 393(6683), 333-339.
44. Evans, B.N.; Rosenblatt, M.I.; Mnayer, L.O.; Oliver, K.R.; Dickerson, I.M. CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors. J. Biol. Chem., 2000, 275(40), 31438-31443.
45. Poyner, D.R.; Hay, D.L.; Conner, A.C. CGRP receptor antagonists: design and screening. Expert Opin. Drug Discov., 2009, 4(12), 1253-1265.
46. Nelson, M.T.; Huang, Y.; Brayden, J.E.; Hescheler, J.; Standen, N.B. Arterial dilations in response to calcitonin gene-related peptide involve activation of K+ channels. Nature, 1990, 344(6268), 770-773.
47. Oliver, K.R.; Wainwright, A.; Edvinsson, L.; Pickard, J.D.; Hill, R.G. Immunohistochemical localization of calcitonin receptor-like receptor and receptor activity-modifying proteins in the human cerebral vasculature. J. Cereb. Blood Flow Metab., 2002, 22(5), 620-629.
48. Lennerz, J.K.; Ruhle, V.; Ceppa, E.P.; Neuhuber, W.L.; Bunnett, N.W.; Grady, E.F.; Messlinger, K. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J. Comp. Neurol., 2008, 507(3), 1277-1299.
49. Williamson, D.J.; Hargreaves, R.J. Neurogenic inflammation in the context of migraine. Microsc. Res. Tech., 2001, 53(3), 167-178.
50. Marvizon, J.C.G.; Perez, O.A.; Song, B.; Chen, W.; Bunnett, N.W.; Grady, E.F.; Todd, A.J. Calcitonin receptor-like receptor and receptor activity modifying protein 1 in the rat dorsal horn: localization in glutamatergic presynaptic terminals containing opioids and adrenergic α2C receptors. Neuroscience, 2007, 148(1), 250-265.
51. Li, J.; Vause, C.V.; Durham, P.L. Calcitonin gene-related peptide stimulation of nitric oxide synthesis and release from trigeminal ganglion glial cells. Brain Res., 2008, 1196, 22-32.
52. Vause, C.V.; Durham, P.L. Calcitonin gene-related peptide differentially regulates gene and protein expression in trigeminal glia cells: findings from array analysis. Neurosci. Lett., 2010, 473(3), 163-167.
53. Aiyar, N.; Daines, R.A.; Disa, J.; Chambers, P.A.; Sauermelch, C.F.; Quiniou, M.-J.; Khandoudi, N.; Gout, B.; Douglas, S.A.; Willette, R.N. Pharmacology of SB-273779, a nonpeptide calcitonin gene-related peptide 1 receptor antagonist. J. Pharmacol. Exp. Ther., 2001, 296(3), 768-775.
54. Nichols, P.L.; Brand, J.; Briggs, M.; D'Angeli, M.; Farge, J.; Garland, S.L.; Goldsmith, P.; Hutchings, R.; Kilford, I.; Li, H.Y.; MacPherson, D.; Nimmo, F.; Sanderson, F.D.; Sehmi, S.; Shuker, N.; Skidmore, J.; Stott, M.; Sweeting, J.; Tajuddin, H.; Takle, A.K.; Trani, G.; Wall, I.D.; Ward, R.; Wilson, D.M.; Witty, D. Potent oxadiazole CGRP receptor antagonists for the potential treatment of migraine. Bioorg. Med. Chem. Lett., 2010, 20(4), 1368-1372.
55. Doods, H.; Hallermayer, G.; Wu, D.; Entzeroth, M.; Rudolf, K.; Engel, W.; Eberlein, W. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br. J. Pharmacol., 2000, 129(3), 420-423.
56. Rudolf, K.; Eberlein, W.; Engel, W.; Pieper, H.; Entzeroth, M.; Hallermayer, G.; Doods, H. Development of human calcitonin gene- related peptide (CGRP) receptor antagonists. 1. potent and selective small molecule CGRP antagonists. 1-[N2-[3,5-dibromo-N- [[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl] carbonyl]- D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)piperazine: the first CGRP antagonist for clinical trials in acute migraine. J. Med. Chem., 2005, 48(19), 5921-5931.
57. Olesen, J.; Diener, H.C.; Husstedt, I.W.; Goadsby, P.J.; Hall, D.; Meier, U.; Pollentier, S.; Lesko, L.M. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med., 2004, 350(11), 1104-1110.
58. Williams, T.M.; Stump, C.A.; Nguyen, D.N.; Quigley, A.G.; Bell, I.M.; Gallicchio, S.N.; Zartman, C.B.; Wan, B.L.; Della Penna, K.; Kunapuli, P.; Kane, S.A.; Koblan, K.S.; Mosser, S.D.; Rutledge, R.Z.; Salvatore, C.; Fay, J.F.; Vacca, J.P.; Graham, S.L. Nonpeptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead. Bioorg. Med. Chem. Lett., 2006, 16(10), 2595-2598.
59. Paone, D.V.; Shaw, A.W.; Nguyen, D.N.; Burgey, C.S.; Deng, J.Z.; Kane, S.A.; Koblan, K.S.; Salvatore, C.A.; Mosser, S.D.; Johnston, V.K.; Wong, B.K.; Miller-Stein, C.M.; Hershey, J.C.; Graham, S.L.; Vacca, J.P.; Williams, T.M. Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-Difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[ 4,5-b]pyridin-1-yl)piperidine-1-carboxamide (MK-0974). J. Med. Chem., 2007, 50(23), 5564-5567.
60. Salvatore, C.A.; Hershey, J.C.; Corcoran, H.A.; Fay, J.F.; Johnston, V.K.; Moore, E.L.; Mosser, S.D.; Burgey, C.S.; Paone, D.V.; Shaw, A.W.; Graham, S.L.; Vacca, J.P.; Williams, T.M.; Koblan, K.S.; Kane, S.A. Pharmacological characterization of MK-0974 [N- [(3R,6S)-6-(2,3-Difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan- 3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl) piperidine- 1-carboxamide], a potent and orally active calcitonin gene- related peptide receptor antagonist for the treatment of migraine. J. Pharmacol. Exp. Ther., 2008, 324(2), 416-421.
61. Ho, T.W.; Ferrari, M.D.; Dodick, D.W.; Galet, V.; Kost, J.; Fan, X.; Leibensperger, H.; Froman, S.; Assaid, C.; Lines, C.; Koppen, H.; Winner, P.K. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet, 2008, 372(9656), 2115-2123.
62. Bell, I.M.; Gallicchio, S.N.; Wood, M.R.; Quigley, A.G.; Stump, C.A.; Zartman, C.B.; Fay, J.F.; Li, C.-C.; Lynch, J.L.; Moore, E.L.; Mosser, S.D.; Prueksaritanont, T.; Regan, C.P.; Roller, S.; Salvatore, C.A.; Kane, S.A.; Vacca, J.P.; Selnick, H.G. Discovery of MK- 3207: a highly potent, orally bioavailable CGRP receptor antagonist. ACS Med. Chem. Lett., 2010, 1(1), 24-29.
63. Salvatore, C.A.,; Moore, E.L.; Calamari, A.; Cook, J.J.; Michener, M.S. O'Malley, S.; Miller, P.J.; Sur, C.; Williams, D.L.; Zeng, Z.; Danziger, A.; Lynch, J.J.; Regan, C.P.; Fay, J.F.; Tang, Y.S.; Li, C.-C.; Pudvah, N.T.; White, R.B.; Bell, I.M.; Gallicchio, S.N.; Graham, S.L.; Selnick, H.G.; Vacca, J.P.; Kane, S.A. Pharmacological properties of 2-[(8R)-8-(3,5-difluorophenyl)-10-oxo-6,9- diazaspiro[4.5]dec-9-yl]-N-[(2R)-2'-oxo-1,1',2',3-tetrahydrospiro [indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl]acetamide (MK-3207), a potent and orally active calcitonin gene-related peptide receptor antagonist. J. Pharmacol. Exp. Ther., 2010, 333(1), 152-160.
64. Hewitt, D.; Aurora, S.; Dodick, D.; Goadsby, P.; Ge, J.; Bachman, R.; Taraborelli, D.; Fan, X.; Assaid, C.; Lines, C.; Ho, T. Efficacy and tolerability of the CGRP receptor antagonist MK-3207 for the acute treatment of migraine: a single attack randomized doubleblind placebo-controlled adaptive dose ranging trial. Cephalalgia, 2009, 29(12), 1350-1351.
65. Degnan, A.P.; Chaturvedula, P.V.; Conway, C.M.; Cook, D.A.; Davis, C.D.; Denton, R.; Han, X.; Macci, R.; Mathias, N.R.; Moench, P.; Pin, S.S.; Ren, S.X.; Schartman, R.; Signor, L.J.; Thalody, G.; Widmann, K.A.; Xu, C.; Macor, J.E.; Dubowchik, G.M. Discovery of (R)-4-(8-Fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N- (3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1- yl)piperidin-1-yl)propan-2-yl)piperidine-1-carboxamide (BMS-694 153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure. J. Med. Chem., 2008, 51(16), 4858-4861.
66. Arulmani, U.; Schuijt, M.P.; Heiligers, J.P.C.; Willems, E.W.; Villalon, C.M.; Saxena, P.R. Effects of the calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS on β-CGRPinduced regional haemodynamic changes in anaesthetised rats. Basic Clin. Pharmacol. Toxicol., 2004, 94(6), 291-297.
67. Kapoor, K.; Arulmani, U.; Heiligers, J.P.C.; Willems, E.W.; Doods, H.; Villalon, C.M.; Saxena, P.R. Effects of BIBN4096BS on cardiac output distribution and on CGRP-induced carotid haemodynamic responses in the pig. Eur. J. Pharmacol., 2003, 475, 69-77.
68. Wu, D.-M.; van Zwieten, P.A.; Doods, H.N. Effects of calcitonin gene-related peptide and BIBN4096BS on myocardial ischemia in anesthetized rats. Acta. Pharmacol. Sin., 2001, 22(7), 588-594.
69. Lynch, J.J.; Regan, C.P.; Edvinsson, L.; Hargreaves, R.J.; Kane, S.A. Comparison of the vasoconstrictor effects of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant (MK- 0974) and zolmitriptan in human isolated coronary arteries. J. Cardiovasc. Pharmacol., 2010, 55(5), 518-521.
70. Edvinsson, L.; Chan, K.Y.; Eftekhari, S.; Nilsson, E.; de Vries, R.; Saveland, H.; Dirven, C.M.F.; Danser, A.H.J.; MaassenVanDen- Brink, A. Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries. Cephalalgia, 2010, 30(10), 1233-1240.
71. Shen, Y.-T.; Mallee, J.J.; Handt, L.K.; Gilberto, D.B.; Lynch, J.J.; Hargreaves, R.J.; Koblan, K.S.; Gould, R.J.; Kane, S.A. Effects of inhibition of β-CGRP receptors on cardiac and peripheral vascular dynamics in conscious dogs with chronic heart failure. J. Cardiovasc. Pharmacol., 2003, 42(5), 656-661.
72. Regan, C.P.; Stump, G.L.; Kane, S.A.; Lynch, J.J. Calcitonin generelated peptide receptor antagonism does not affect the severity of myocardial ischemia during atrial pacing in dogs with coronary artery stenosis. J. Pharmacol. Exp. Ther., 2009, 328(2), 571-578.
73. Lynch, J.J.; Shen, Y.-T.; Pittman, T.J.; Anderson, K.D.; Koblan, K.S.; Gould, R.J.; Regan, C.P.; Kane, S.A. Effects of the prototype serotonin 5-HT1B/1D receptor agonist sumatriptan and the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP8-37 on myocardial reactive hyperemic response in conscious dogs. Eur. J. Pharmacol., 2009, 623, 96-102.
74. Hoare, S.R.J. Mechanisms of peptide and nonpeptide ligand binding to class B G-protein-coupled receptors. Drug Discov. Today, 2005, 10(6), 417-427.
75. Miller, L.J. Informed development of drugs acting at family B G protein-coupled receptors. Ann. N.Y. Acad. Sci., 2008, 1144, 203-209.
76. Fraser, N.J.; Wise, A.; Brown, J.; McLatchie, L.M.; Main, M.J.; Foord, S.M. The amino terminus of receptor activity modifying proteins is a critical determinant of glycosylation state and ligand binding of calcitonin receptor-like receptor. Mol. Pharmacol., 1999, 55(6), 1054-1059.
77. Hershey, J.C.; Corcoran, H.A.; Baskin, E.P.; Salvatore, C.A.; Mosser, S.; Williams, T.M.; Koblan, K.S.; Hargreaves, R.J.; Kane, S.A. Investigation of the species selectivity of a nonpeptide CGRP receptor antagonist using a novel pharmacodynamic assay. Regul. Pept., 2005, 127, 71-77.
78. Akerman, S.; Kaube, H.; Goadsby, P.J. Vanilloid type 1 receptors (VR1) on trigeminal sensory nerve fibres play a minor role in neurogenic dural vasodilatation, and are involved in capsaicin-induced dural dilation. Br. J. Pharmacol., 2003, 140(4), 718-724.
79. Sinclair, S.R.; Kane, S.A.; Van der Schueren, B.J.; Xiao, A.; Willson, K.J.; Boyle, J.; de Lepeleire, I.; Xu, Y.; Hickey, L.; Denney, W.S.; Li, C.-C.; Palcza, J.; Vanmolkot, F.H.M.; Depre, M.; Van Hecken, A.; Murphy, M.G.; Ho, T.W.; de Hoon, J.N. Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974). Br. J. Clin. Pharmacol., 2010, 69(1), 15-22.
80. Ho, T.W.; Mannix, L.K.; Fan, X.; Assaid, C.; Furtek, C.; Jones, C.J.; Lines, C.R.; Rapoport, A.M. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology, 2008, 70(16), 1304-1312.
81. Mallee, J.J.; Salvatore, C.A.; LeBourdelles, B.; Oliver, K.R.; Longmore, J.; Koblan, K.S.; Kane, S.A. Receptor activitymodifying protein 1 determines the species selectivity of non- peptide CGRP receptor antagonists. J. Biol. Chem., 2002, 277(16), 14294-14298.
82. Miller, P.S.; Barwell, J.; Poyner, D.R.; Wigglesworth, M.J.; Garland, S.L.; Donnelly, D. Non-peptidic antagonists of the CGRP receptor, BIBN4096BS and MK-0974, interact with the calcitonin receptor- like receptor via methionine-42 and RAMP1 via tryptophan- 74. Biochem. Biophys. Res. Commun., 2010, 391(1), 437-442.
83. Salvatore, C.A.; Mallee, J.J.; Bell, I.M.; Zartman, C.B.; Williams, T.M.; Koblan, K.S.; Kane, S.A. Identification and pharmacological characterization of domains involved in binding of CGRP receptor antagonists to the calcitonin-like receptor. Biochem., 2006, 45(6), 1881-1887.
84. Christopoulos, G.; Perry, K.J.; Morfis, M.; Tilakaratne, N.; Gao, Y.; Fraser, N.J.; Main, M.J.; Foord, S.M.; Sexton, P.M. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol. Pharmacol., 1999, 56, 235-242.
85. Muff, R.; Buhlmann, N.; Fischer, J.A.; Born, W. An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3. Endocrinology, 1999, 140(6), 2924-2927.
86. Kusano, S.; Kukimoto-Niino, M.; Akasakam, R.; Toyama, M.; Terada, T.; Shirouzu, M.; Shindo, T.; Yokoyama, S. Crystal structure of the human receptor activity-modifying protein 1 extracellular domain. Protein Sci., 2008, 17(11), 1907-1914.
87. Moore, E.L.; Gingell, J.J.; Kane, S.A.; Hay, D.L.; Salvatore, C.A. Mapping the CGRP receptor ligand binding domain: tryptophan-84 of RAMP1 is critical for agonist and antagonist binding. Biochem. Biophys. Res. Commun., 2010, 394(1), 141-145.
88. Koth, C.M.; Abdul-Manan, N.; Lepre, C.A.; Connolly, P.J.; Yoo, S.; Mohanty, A.K.; Lippke, J.A.; Zwahlen, J.; Coll, J.T.; Doran, J.D.; Garcia-Guzman, M.; Moore, J.M. Refolding and characterization of a soluble ectodomain complex of the calcitonin gene-related peptide receptor. Biochem., 2010, 49(9), 1862-1872.
89. Caron, K.M.; Smithies, O. Extreme hydrop fetalis and cardiovascular abnormalities in mice lacking a functional adrenomedullin gene. Proc. Natl. Acad. Sci., 2001, 98(2), 615-619.
90. Dackor, R.; Fritz-Six, K.; Smithies, O.; Caron, K. Receptor activity- modifying proteins 2 and 3 have distinct physiological functions from embryogenesis to old age. J. Biol. Chem., 2007, 282(25), 18094-18099.
91. Ichikawa-Shindo, Y.; Sakurai, T.; Kamiyoshi, A.; Kawate, H.; Iinuma, N.; Yoshizawa, T.; Koyama, T.; Fukuchi, J.; Iimuro, S.; Moriyama, N.; Kawakami, H.; Murata, T.; Kangawa, K.; Nagai, R.; Shindo, T. The GPCR modulator protein RAMP2 is essential for angiogenesis and vascular integrity. J. Clin. Invest., 2008, 118(1), 29-39.
92. Zeller, J.; Poulsen, K.T.; Sutton, J.E.; Abdiche, Y.N.; Collier, S.; Chopra, R.; Garcia, C.A.; Pons, J.; Rosenthal, A.; Shelton, D.L. CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat. Br. J. Pharmacol., 2008, 155(7), 1093-1103.
93. Petersen, K.A.; Birk, S.; Lassen, L.H.; Kruuse, C.; Jonassen, O.; Lesko, L.; Olesen, J. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia, 2005, 25(2), 139-147.
94. Boehringer Ingelheim Pharmaceuticals. BI 44370 TA in Acute Migraine Attack. ClinicalTrials.gov identifier NCT00751803.
95. Connor, K.M.; Shapiro, R.E.; Diener, H.-C.; Lucas, S.; Kost, J.; Fan, X.; Fei, K.; Assaid, C.; Lines, C.; Ho, T.W. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology, 2009, 73(12), 970-977.
96. Ho, T.; Connor, K.; Dahlof, C.; Loeys, T.; Jones, C.; Giezek, H.; Massaad, R.; Williams-Diaz, A.; Ramadan, N. Assessment of the long term safety and tolerability of telcagepant for the intermittent treatment of acute migraine: a double-blind, active-controlled study. Cephalalgia, 2009, 29(Suppl. 1), 12.
97. Storer, R.J.; Akerman, S.; Goadsby, P.J. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br. J. Pharmacol., 2004, 142(7), 1171-1181.
98. Fischer, M.J.M.; Koulchitsky, S.; Messlinger, K. The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus. J. Neurosci., 2005, 25(25), 5877-5883.
99. Levy, D.; Burstein, R.; Strassman, A.M. Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann. Neurol., 2005, 58(5), 698-705.
100. Rahmann, A.; Wienecke, T.; Hansen, J.M.; Fahrenkrug, J.; Olesen, J.; Ashina, M. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia, 2008, 28(3), 226-236.
101. Edvinsson, L. CGRP blockers in migraine therapy: where do they act? Br. J. Pharmacol., 2008, 155(7), 967-969.
102. Grimwood, S.; Hartig, P.R. Target site occupancy: emerging generalizations from clinical and preclinical studies. Pharmacol. Ther., 2009, 122(3), 281-301.
103. Sur, C.; Hargreaves, R.; Bell, I.; Dancho, M.; Graham, S.; Hostetler, E.; Kane, S.; Kim, J.; Michener, M.; Miller, P.; O'Malley, S.; Salvatore, C.; Selnick, H.; Staas, D.; Stump, C.; Williams, D.; Wood, M.; Zeng, Z.; Cook, J. CSF levels and binding pattern of novel CGRP receptor antagonists in rhesus monkey and human central nervous system: toward the development of a PET tracer. Cephalalgia, 2009, 29(Suppl. 1), 136.